G&T Investment

Construction of the cGMP Standard HSC Stem Cell Technology Platform-HOSTEP Kicks Off

Fri, 08 Nov 2024 16:04:00 | Print | Email Share:

A groundbreaking ceremony for the HSC Stem Cell Technology Platform (HOSTEP) was held at plot no. RD6-3, Research and Development Zone, Hoa Lac Hi-Tech Park,Hanoi, Vietnam on November 7 to mark the start of construction.

The event was organized by Hoa Lac Stem Cell Joint Stock Company (HSC), a pioneer in the field of reproductive biotechnology and stem cell technology in Vietnam. This event marks a significant milestone for HSC in its mission to promote the production and application of advanced stem cell technology to support research and treatment in Vietnam.

Speaking at the event, Dr. Bui Xuan Nguyen, Chairman of HSC, shared that HOSTEP embodies the dedication of the research team and the collaboration between Vietnamese and international partners committed to making stem cell technology a cornerstone of Vietnam’s modern medical system.

GC Therapeutics Emerges with $75M to Launch Off-the-Shelf iPSC-Derived Cell Therapies at Scale

September 25, 2024 By Cade Hildreth (CEO) Leave a Comment

CAMBRIDGE, Mass.— GC Therapeutics, Inc. (GCTx), announced its launch to scale and unlock the next generation of cell therapy. Invented and developed by a world-class team of scientists in the lab of professor George Church, Ph.D., at Harvard Medical School and the Wyss Institute, GCTx’s induced pluripotent stem cell (iPSC) programming platform, TFome™ (Transcription-Factor-ome, pronounced as tee-eff-ome), integrates the latest advancements in synthetic biology, gene editing, cell engineering and machine learning to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of disease areas.

GCTx completed a $65 million Series A financing led by Cormorant Asset Management with participation from Mubadala Capital, Andreessen Horowitz (a16z) Bio + Health, Medical Excellence Capital, Cercano Management and Pear VC, bringing total capital raised by GCTx to $75 million.

GoLiver Therapeutics is the winner of the France 2030

25/09/2024

GoLiver Therapeutics is the winner of the France 2030 “innovation in Biotherapies and Bioproduction” call for its GOCLINICALS project, dedicated to a novel stem cell-based liver therapy

GoLiver Therapeutics has been awarded €1.6m from France 2030 to progress its first biomedicine, developed from pluripotent stem cells, into the clinic for the treatment of severe liver failures.

Nantes, France, September 25th 2024 – GoLiver Therapeutics, a start-up focused on the development of advanced therapy medicinal products and the industrial processes necessary for their manufacturing, is pleased to announce that it has won the “Innovations in Biotherapies and Bioproduction” call for proposal launched by the French government to make France a European leader in the biotherapy sector. The start-up will receive a €1.6 million investment from France 2030.

Novo Nordisk bets $600M biobucks on NanoVation's ability to take genetic medicines beyond the liver

By Nick Paul Taylor Sep 18, 2024 9:03am

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting cells outside the liver.

The Danish Big Pharma has shifted the focus of its pipeline in recent years. Having made its name with peptides and proteins, the company has expanded its pipeline to cover modalities including small molecules, RNAi therapies and gene editing. Novo has used many of the novel modalities as part of its concurrent move deeper into rare diseases.

Sep 4, 2024

ArsenalBio raises $325M for solid tumor CAR-T science with Regeneron and BMS in tow

The South San Francisco biotech has two candidates in clinical trials, AB-1015 in phase I for ovarian cancer - with initial data due later this year – but is currently focusing most of its attention on AB-2100, which recently started a phase 1/2 study in kidney cancer, and bringing forward a preclinical-stage programme in prostate cancer.

To date, T cell therapies such as CAR-Ts have made big strides forward in the treatment of blood cancers, but have struggled in solid tumours because of targeting and infiltration difficulties, and challenges in surviving the hostile microenvironment around the tumour mass.

Columbia University Given Record $400 Million For ...

https://www.forbes.com › sites › co...

22 août 2024 — A portion of the gift will be used to boost funding for the medical school's programs in cell engineering and gene therapy.

Columbia University received a $400 million gift from Roy and Diana Vagelos, which is the single largest ever made to Columbia’s medical school. A principal function of this gift will be to significantly expand the mission of the Vagelos-funded institute created in 2023, according to a Columbia spokesperson.n addition, the ...

Novo Nordisk Foundation Center for Stem Cell Medicine ...

Novo Nordisk Foundation Center for Stem Cell Medicine

https://renew.ku.dk

·Traduire cette page

Learn more about reNEW, a major international research center focused on stem cell medicine, funded by the Novo Nordisk Foundation.

The Novo Nordisk Foundation has identified stem cell medicine as a major opportunity in biomedical science. Stem cell medicine products require high quality research in stem cell and developmental biology. However, the path from scientific discovery to final market-ready product is usually long, slow and expensive.

reNEW is built on the prior support of stem cell research within Denmark, created as a tripartite collaborative research network between three internationally leading Institutions: The University of Copenhagen (Copenhagen, Denmark), Leiden University Medical Centre (Leiden, The Netherlands), and the Murdoch Children’s Research Institute (Melbourne, Australia).

Given the long history of stem cell science within the University of Copenhagen, supported by the Novo Nordisk Foundation, the research teams within reNEW from the University of Copenhagen were identified based on their research excellence in stem cell biology and their poised position with respect to stem cell medicine.

TODAY’S BIG NEWS

JUL 15, 2024

Artiva sets out $135M IPO plans to push NK cell therapy through trials

Artiva Biotherapeutics is hoping to rake in up to $135 million from a planned IPO, with the proceeds ear-marked for automimmune clinical trials for a lead allogeneic natural killer (NK) cell therapy.

San Diego-based Artiva unveiled the plans in a Securities and Exchange Commission filing at the end of June, but only this morning set out its expectations of selling 8.7 million shares priced between $14 and $16 apiece.

Assuming that the final price falls in the middle of this range, this will bring the biotech $116.8 million in net proceeds—rising to $135 million if underwriters take up their 30-day option to buy an additional 1.3 million shares at the same price of $15.

GMP Laboratory

In May, REPROCELL USA proudly inaugurated its new GMP BioManufacturing Laboratory. This state-of-the-art facility features a BioSpherix Cytocentric Xvivo system, enabling the production of hiPSCs and hMSCs in a contamination-free environment.

Read more

By California Institute for Regenerative Medicine (CIRM) on September 10, 2024

The California Institute for Regenerative Medicine (CIRM) is proud to announce the allocation of $26 million to support clinical research targeting a range of cancers, heart conditions, and rare diseases. This significant funding underscores CIRM’s commitment to advancing innovative stem cell and gene therapy-based treatments through all stages of clinical trial development.

This latest round of awards will support five projects within CIRM’s Clinical program, which aims to provide critical funding for eligible projects at various stages of their development. These new awards bring the total number of CIRM-funded clinical trials to 108, highlighting our ongoing dedication to fostering groundbreaking research and transformative therapies.